Alkem Laboratories transfers generics business to wholly owned subsidiary

Alkem Laboratories Limited has officially entered into a business transfer agreement with Alkem Wellness Limited, a wholly-owned subsidiary, for the transfer of its trade generics business. This transaction, previously intimated on December 10, 2024, is structured as a slump sale on a going concern basis. The agreement was executed on September 26, 2025.

The transfer of the trade generics business will become effective from October 1, 2025. This move is part of an ongoing corporate strategy to streamline operations and is disclosed in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further information regarding this development is accessible on the company's website, www.alkemlabs.com. Manish Narang, president - legal, company secretary & compliance officer, issued the disclosure on behalf of Alkem Laboratories Limited.